Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CCTG BL.13
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
- NCT03768570 ↗
- Active, not recruiting
- Canadian Cancer Trials Group
- Focused
We haven't built an HCP commentary report on CCTG BL.13 (durvalumab in Bladder Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CCTG BL.13 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Durvalumab
- Arms
- Surveillance · No intervention
- Durvalumab · Active comparator
- Enrollment
- 82
- Primary outcomes
- Disease-free survival
- Sponsor
- Canadian Cancer Trials Group with AstraZeneca
- Start
- Oct 25, 2019
- Primary completion
- Oct 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03768570 · updated Jun 18, 2026